Alaunos Therapeutics (TCRT) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Alaunos Therapeutics (TCRT) over the last 15 years, with Q3 2025 value amounting to -$1.9 million.
- Alaunos Therapeutics' Enterprise Value fell 1515.15% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 million, marking a year-over-year decrease of 1515.15%. This contributed to the annual value of -$1.1 million for FY2024, which is 8200.26% up from last year.
- Per Alaunos Therapeutics' latest filing, its Enterprise Value stood at -$1.9 million for Q3 2025, which was down 1515.15% from -$2.9 million recorded in Q2 2025.
- Over the past 5 years, Alaunos Therapeutics' Enterprise Value peaked at -$319000.0 during Q1 2025, and registered a low of -$100.1 million during Q1 2021.
- Over the past 5 years, Alaunos Therapeutics' median Enterprise Value value was -$18.3 million (recorded in 2023), while the average stood at -$35.1 million.
- Examining YoY changes over the last 5 years, Alaunos Therapeutics' Enterprise Value showed a top increase of 9230.4% in 2025 and a maximum decrease of 1689.0% in 2025.
- Quarter analysis of 5 years shows Alaunos Therapeutics' Enterprise Value stood at -$76.1 million in 2021, then surged by 30.32% to -$53.0 million in 2022, then soared by 88.56% to -$6.1 million in 2023, then surged by 82.0% to -$1.1 million in 2024, then tumbled by 77.64% to -$1.9 million in 2025.
- Its Enterprise Value stands at -$1.9 million for Q3 2025, versus -$2.9 million for Q2 2025 and -$319000.0 for Q1 2025.